Patient Care         Medical University       Research at MUSC

MUSC logo   Research News

Hollings Cancer CenterThe Medical University of South Carolina (MUSC) Hollings Cancer Center has attained National Cancer Institute (NCI) designation, a distinction held by only 63 other cancer centers in the U.S. The Hollings Cancer Center (HCC) is the only institution in South Carolina with this prestigious status.

Being named one of the top cancer research centers in the country signals that MUSC/HCC researchers and physicians are leaders in discovering, developing, and delivering cutting-edge treatments based on laboratory research to patients in South Carolina and beyond. The immediate benefit to patients is increased access to early clinical trials offering promising new treatments.

NCI designation is accompanied by more than $7 million in funding to sustain and grow research efforts at MUSC. The NCI awarded designation to HCC based on its outstanding facilities, commitment to research, leadership, and vision.

NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate diverse research approaches that focus on cancer. They play a vital role in advancing the goal of reducing morbidity and mortality from cancer through increased clinical trials that offer patients new drugs and treatment protocols that would be unavailable to them otherwise.

Designation also holds the potential to spur South Carolina’s economy by attracting public and private funding for new endeavors.

podcasts Related Podcasts:

- Dr. Andrew Kraft, the Hollings Cancer Center Director, explains the significance of the designation and the importance of this designation for MUSC patients.

- Dr. Jerry Reves, the Dean of the College of Medicine and VP for Medical Affairs, talks about the leadership and teamwork required for the MUSC Hollings Cancer Center to become the 64th Cancer Center in the country to receive the National Cancer Institute Designation.

- Dr. Rob Stuart and Dr. Dan Fernandes discuss major breakthroughs in research for chronic lymphocytic leukemia and acute myeloid leukemia.

Holling Cancer Center website